VectorY Therapeutics Raises €74.5Mn to Advance Antibody Treatments for Neurodegenerative Diseases

The funding round included several new investors, such as Angelini Ventures, Dutch development finance institution Invest-NL and the European Investment Bank (EIB).

Existing investors also joined the round. These include Forbion, through its Growth and Ventures strategies, EQT Life Sciences, MRL Ventures, Insight Partners, BGV, Eli Lilly and Company, and the ALS Investment Fund.

“Neurodegenerative diseases represent some of the most complex challenges in medicine, and patients and families urgently need new treatment options. This financing reflects strong confidence in our team, our platform and the potential of our pipeline,” said Jim Scibetta, chief executive officer, VectorY.

“We believe VectorY is building a compelling approach to one of the most challenging areas of medicine. Its progress with VTx-002, including the expansion of the PIONEER-ALS study, is an important step in evaluating the program’s potential. This financing will help the company advance that work while developing additional programs, including VTx-003 for Huntington’s disease. We are pleased to continue supporting VectorY as it translates its platform into potential pioneering treatment options for people living with neurodegenerative diseases,” said Wouter Joustra, General Partner at Forbion.

Founded in 2020, VectorY Therapeutics is based at the Science Park Matrix Innovation Centre in Amsterdam. The company develops targeted treatments for neurodegenerative diseases, which affect the brain and nervous system. Its goal is to slow down or potentially reverse the progression of these conditions.

The company has developed its own technology platform that combines specially designed antibodies with a one-time gene delivery method called adeno-associated virus (AAV).

This method delivers the treatment directly to the central nervous system, which includes the brain and spinal cord. VectorY calls this technology "vectorised antibodies".

According to the company, this approach could overcome some of the challenges faced by existing treatments. These include delivering drugs to the right parts of the brain, making treatments last longer and reaching the specific targets linked to disease progression.

Read Also- AI Startup Opdo Secures $2.3Mn to Transform Optical Engineering